Post-Exposure Prophylaxis (PEP) for Human Immunodeficiency Virus (HIV)

Developed in collaboration with CASA Medical.

Guideline applies to certificate holders, Aviation medical examiners and assessors care providers to understand the aeromedical significance of PEP treatment.

Human immunodeficiency virus (HIV) post-exposure prophylaxis (PEP) following potential or known exposure to HIV in sexual, occupational, and non-occupational settings utilises a first-line two-drug regimen of co-formulated tenofovir disoproxil (TD) and emtricitabine (FTC), with the addition of dolutegravir 50 mg daily OR raltegravir 1200 mg daily for 28 days when three-drug PEP is recommended.

This protocol refers to PEP treatments that include:

• Two drug regimen of TD/FTC
• Three drug regimen of TD/FTC plus dolutegravir OR raltegravir

This medication is generally well tolerated. Do not stop taking your medication unless directed by your doctor. After initiating PEP HIV laboratory testing is undertaken at 4 –6 weeks and 3 months after exposure.

Pilot and controller information

Pilots or controllers must stop flying or operating and contact their ME if:

• They commence PEP and should not fly or operate for a minimum period of 1 week to assess medication suitability and side effects.
• They experience significant headache, fatigue, gastrointestinal upset, and muscle pains stop.
• There are any safety relevant abnormal testing results.

For more information, see Medical Manual: HIV - Post-Exposure Prophylaxis (PEP).